Collegium Pharmaceutical, Inc. COLL Net debt / EBITDA

Net debt / EBITDA at other companies

Indivior Pharmaceuticals, Inc.INDV

1×+0.9×

Pacira BioSciences, Inc.PCRX

2.3×—

BioventusBVS

2.3×-2.7×

OrganonOGN

6×+0.4×

Cumberland PharmaceuticalsCPIX

-6.6×—

Supernus PharmaceuticalsSUPN

-3.9×-4.7×

FAQ

What is Collegium Pharmaceutical, Inc.'s net debt / EBITDA?

Collegium Pharmaceutical, Inc. (COLL) reported net debt / EBITDA of -0.5× in Q2 2026.

How has Collegium Pharmaceutical, Inc.'s net debt / EBITDA changed year-over-year?

Collegium Pharmaceutical, Inc.'s net debt / EBITDA decreased by 34.1% year-over-year, from -0.4× to -0.5×.

What is the long-term trend for Collegium Pharmaceutical, Inc.'s net debt / EBITDA?

Over 5 years (2020 to 2025), Collegium Pharmaceutical, Inc.'s net debt / EBITDA has grown at a -17.8% compound annual growth rate (CAGR), from -2.2× to -0.8×.

What does net debt / EBITDA mean?

Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.